Jupiter BioVentures Announces Breakthrough with Deimos Product

Revolutionary Advancements in Radioprotection

San Francisco, CA - July 28, 2024 - Jupiter BioVentures proudly announces the latest breakthrough in their Deimos product line. Leveraging their position as a leader in biotech innovation, Jupiter BioVentures continues to pioneer advancements in medical treatments through strategic partnerships and cutting-edge research.

Global Licensing Agreement for Lerociclib

Jupiter BioVentures' portfolio company, Deimos Biosciences, has entered into a significant global licensing agreement for lerociclib, excluding the Asia-Pacific region. Lerociclib is a potent CDK4/6 inhibitor known for its effectiveness in radioprotective applications, promising increased survival rates for individuals exposed to radiation. This partnership highlights Jupiter BioVentures' commitment to addressing critical unmet medical needs on a global scale.

Enhanced Treatment for Breast Cancer

The Deimos product line is setting new standards in oncology with lerociclib, which has demonstrated superior clinical activity and tolerability in treating hormone receptor-positive, HER2-negative breast cancer. The product’s increased selectivity and potency offer a differentiated clinical profile, making it a leading candidate in next-generation cancer treatments.

Exclusive Development and Commercialization Rights

Under the terms of the agreement, Deimos Biosciences holds the exclusive rights to develop, manufacture, and commercialize lerociclib across the US, Europe, and Japan. This strategic move positions Deimos Biosciences to significantly impact the oncology market and improve patient outcomes worldwide.

About Jupiter BioVentures

Jupiter BioVentures specializes in creating transformative biotech companies from the ground up. By identifying and nurturing innovative ideas from top biotech pioneers, Jupiter BioVentures aims to tackle some of the most challenging health issues through its robust portfolio of companies and products.

For more information, visit Jupiter BioVentures.